(Q33835863)

English

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening (English)

1 reference

Europe PubMed Central

29 July 2017

prostate cancer

1 reference

based on heuristic

inferred from title

object named as

Andrew J Vickers

5

0 references

object named as

Hans Lilja

2

0 references

author name string

Caroline J Savage

1

1 reference

Europe PubMed Central

29 July 2017

Angel M Cronin

3

1 reference

Europe PubMed Central

29 July 2017

David Ulmert

4

1 reference

Europe PubMed Central

29 July 2017

publication date

20 April 2010

1 reference

Europe PubMed Central

29 July 2017

Cancer Epidemiology, Biomarkers & Prevention

1 reference

Europe PubMed Central

29 July 2017

19

1 reference

Europe PubMed Central

29 July 2017

5

1 reference

Europe PubMed Central

29 July 2017

1201-1207

1 reference

Europe PubMed Central

29 July 2017

Prostate cancer: estimating the benefits of PSA screening

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

4 July 2018

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

4 July 2018

Screening and prostate-cancer mortality in a randomized European study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

4 July 2018

Mortality results from a randomized prostate-cancer screening trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

4 July 2018

Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

4 July 2018

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

4 July 2018

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

4 July 2018

Overdiagnosis in early detection programs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

4 July 2018

Lead time associated with screening for prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

4 July 2018

Prostate-specific antigen testing of older men.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

4 July 2018

Screening for prostate cancer: estimating the magnitude of overdetection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

4 July 2018

Natural History of Changes in Prostate Specific Antigen in Early Stage Prostate Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

4 July 2018

Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

4 July 2018

Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

29 October 2018

Screening for prostate cancer--the controversy that refuses to die.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

29 October 2018

Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

29 October 2018

Computational methods in medical decision making: to screen or not to screen?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

29 October 2018

MISCAN: estimating lead-time and over-detection by simulation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

29 October 2018

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

29 October 2018

Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

29 October 2018

Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened P

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866147

29 October 2018

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

1 reference

https://pubmed.ncbi.nlm.nih.gov/20406957

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20406957

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1055-9965.EPI-09-1251

1 reference

Europe PubMed Central

29 July 2017

release_5quhprpwmbhati7cjd6cecxmyy

1 reference

https://api.fatcat.wiki/v0/release/5quhprpwmbhati7cjd6cecxmyy

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33835863&oldid=1966893489"